Bioequivalence Study of Two Formulations of Rivaroxaban Tablets 20 mg in Healthy Male Volunteers Under Fed Conditions

• ClinicalTrials.gov Identifier: NCT04729998
• Recruitment Status: Not yet recruiting
• First Posted: January 29, 2021
• Last Update Posted: January 29, 2021
• Sponsor: Pharmtechnology LLC
• Collaborator: ClinPharmInvest, LLC
• Information provided by (Responsible Party): Pharmtechnology LLC

Study Description

Brief Summary:

This is an open-labeled, laboratory-blinded, randomized, two period, single-center, crossover, comparative study, where each participant will be randomly assigned to the reference (Xarelto®, 20 mg film-coated tablets) or the test (Rivaroxaban, 20 mg film-coated tablets) formulation in each period of study (sequences Test-Reference (TR) or Reference-Test (RT)), in order to evaluate if both formulations are bioequivalent.

Condition or disease	Intervention/treatment	Phase
Bioequivalence	Drug: Rivaroxaban film-coated tablet 20 mg; Drug: Xarelto® film-coated tablet 20 mg	Phase 1

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 34 participants
• Allocation: Randomized
• Intervention Model: Crossover Assignment
• Masking: Single (Outcomes Assessor)
• Primary Purpose: Other
• Official Title: Randomized Crossover 2-Period Single-dose BE Study of Rivaroxaban Film-coated Tablets 20mg (Pharmtechnology LLC, Republic of Belarus) and Xarelto® Film-coated Tablets 20mg (Bayer AG, Germany) in Healthy Male Volunteers Under Fed Conditions
• Estimated Study Start Date: January 30, 2021
• Estimated Primary Completion Date: February 15, 2021
• Estimated Study Completion Date: February 15, 2021

Arms and Interventions

Arm	Intervention/treatment
Sequence TR; 17 subjects assigned to the sequence TR will receive a single 20 mg dose of the test product Rivaroxaban (1 x 20 mg tablet), marked as T in the sequence, in Period 1 and a single 20 mg dose of the reference product Xarelto® (1 x 20 mg tablet), marked as R in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a standardized breakfast. The tablet must be swallowed whole and must not be chewed or broken.	Drug: Rivaroxaban film-coated tablet 20 mg; Rivaroxaban is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 20 mg of rivaroxaban.; Other Name: The test product; Drug: Xarelto® film-coated tablet 20 mg; Xarelto® is manufactured by Bayer AG, Germany. Each tablet contains 20 mg of rivaroxaban.; Other Name: The reference product
Sequence RT; 17 subjects assigned to the sequence RT will receive a single 20 mg dose of the reference product Xarelto® (1 x 20 mg tablet), marked as R in the sequence, in Period 1 and a single 20 mg dose of the test product Rivaroxaban (1 x 20 mg tablet), marked as T in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a standardized breakfast. The tablet must be swallowed whole and must not be chewed or broken.	Drug: Rivaroxaban film-coated tablet 20 mg; Rivaroxaban is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 20 mg of rivaroxaban.; Other Name: The test product; Drug: Xarelto® film-coated tablet 20 mg; Xarelto® is manufactured by Bayer AG, Germany. Each tablet contains 20 mg of rivaroxaban.; Other Name: The reference product

Outcome Measures

Primary Outcome Measures :

1. Cmax of rivaroxaban in plasma after administration of the test and the reference products. [ Time Frame: Time points 0.00 (prior to each drug administration) and 0.17, 0.33, 0.67, 1.00, 1.33, 1.67, 2.00, 2.33, 2.67, 3.00, 3.33, 3.67, 4.00, 4.50, 5.00, 5.30, 6.00, 8.00, 12.00, 16.00, 24.00, 36.00. 48.00 hours after each drug administration. ]
   Maximum observed concentration in plasma.
2. AUC0-t of rivaroxaban in plasma after administration of the test and the reference. [ Time Frame: Time points 0.00 (prior to each drug administration) and 0.17, 0.33, 0.67, 1.00, 1.33, 1.67, 2.00, 2.33, 2.67, 3.00, 3.33, 3.67, 4.00, 4.50, 5.00, 5.30, 6.00, 8.00, 12.00, 16.00, 24.00, 36.00. 48.00 hours after each drug administration. ]
   Cumulative area under the concentration time curve calculated from 0 to time of last observed quantifiable concentration using the linear trapezoidal method

Secondary Outcome Measures :

1. Tmax of rivaroxaban in plasma after administration of the test and the reference products. [ Time Frame: Time points 0.00 (prior to each drug administration) and 0.17, 0.33, 0.67, 1.00, 1.33, 1.67, 2.00, 2.33, 2.67, 3.00, 3.33, 3.67, 4.00, 4.50, 5.00, 5.30, 6.00, 8.00, 12.00, 16.00, 24.00, 36.00. 48.00 hours after each drug administration. ]
   Time of maximum observed concentration; if it occurs at more than one time point, Tmax is defined as the first time point with this value.
2. AUC0-INF of rivaroxaban in plasma after administration of the test and the reference products. [ Time Frame: Time points 0.00 (prior to each drug administration) and 0.17, 0.33, 0.67, 1.00, 1.33, 1.67, 2.00, 2.33, 2.67, 3.00, 3.33, 3.67, 4.00, 4.50, 5.00, 5.30, 6.00, 8.00, 12.00, 16.00, 24.00, 36.00. 48.00 hours after each drug administration. ]
   Area under the concentration time curve extrapolated to infinity, calculated as AUC0-t + ĈLQC (the predicted concentration at time TLQC) / λZ (apparent elimination rate constant).
3. Residual area of rivaroxaban in plasma after administration of the test and the reference products. [ Time Frame: Time points 0.00 (prior to each drug administration) and 0.17, 0.33, 0.67, 1.00, 1.33, 1.67, 2.00, 2.33, 2.67, 3.00, 3.33, 3.67, 4.00, 4.50, 5.00, 5.30, 6.00, 8.00, 12.00, 16.00, 24.00, 36.00. 48.00 hours after each drug administration. ]
   Extrapolated area (AUCresid%=100%*(AUC0-INF - AUC0-t)/AUC0-INF).
4. λZ of rivaroxaban in plasma after administration of the test and the reference products. [ Time Frame: Time points 0.00 (prior to each drug administration) and 0.17, 0.33, 0.67, 1.00, 1.33, 1.67, 2.00, 2.33, 2.67, 3.00, 3.33, 3.67, 4.00, 4.50, 5.00, 5.30, 6.00, 8.00, 12.00, 16.00, 24.00, 36.00. 48.00 hours after each drug administration. ]
   Apparent elimination rate constant.
5. Terminal elimination half-life (T1/2) of rivaroxaban in plasma after administration of the test and the reference products. [ Time Frame: Time points 0.00 (prior to each drug administration) and 0.17, 0.33, 0.67, 1.00, 1.33, 1.67, 2.00, 2.33, 2.67, 3.00, 3.33, 3.67, 4.00, 4.50, 5.00, 5.30, 6.00, 8.00, 12.00, 16.00, 24.00, 36.00. 48.00 hours after each drug administration. ]
   Terminal elimination half-life, calculated as ln(2)/λZ.

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 45 Years (Adult)
• Sexes Eligible for Study: Male
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

1. healthy caucasian men aged between 18 to 45 years;
2. verified diagnosis "healthy" according to the anamnesis data and the results of standard clinical, laboratory and instrumental examination methods, physical examination and anamnestic examination;
3. body mass index 18.5-30 kg/m²;
4. the results of an X-ray or fluorographic examination of the chest organs within the normal range (the results of an examination carried out within 12 months before the start of the study may be provided);
5. consent to use a double barrier method of contraception (condom + spermicide) or complete sexual abstinence, as well as consent not to take part in sperm donation from the moment of taking the drug in the first period, during the entire study and within 14 days after taking the drug in the second period research;
6. subjects are able to understand the requirements of the study, to sign a written informed consent, and also to accept all the restrictions imposed during the course of the study, and to agree to return for the required investigations.

Exclusion Criteria:

1. burdened allergic history, hypersensitivity to rivaroxaban or excipients that are part of any of the investigational drugs, or intolerance to these components;
2. clinically significant pathologies of the cardiovascular, bronchopulmonary, neuroendocrine systems, as well as diseases of the gastrointestinal tract, liver, kidneys and blood;
3. other diseases that, in the opinion of the researcher, may affect the absorption, distribution, metabolism or excretion of both drugs, or increase the risk of negative consequences for the volunteer;
4. a history of brain or spinal cord injury, recent surgery on the brain, spinal cord or eyes;
5. history of internal bleeding of any genesis;
6. a history of coagulation disorders (eg, von Willebrand disease, hemophilia);
7. hereditary intolerance to lactose or galactose (for example, congenital lactase deficiency or glucose-galactose malabsorption), since the composition of the tested and reference drugs includes lactose monohydrate;
8. the presence of mental disorders, including a history;
9. seizures, epilepsy and any other neurological disorders in history;
10. surgical interventions on the gastrointestinal tract, with the exception of appendectomy;
11. acute infectious diseases that ended less than 4 weeks before taking the drug in the first period;
12. dehydration due to diarrhea, vomiting or other reason within the last 24 hours before taking the drug in the first period of the study. Moreover, if vomiting or diarrhea was a manifestation of an infectious disease, then participation in the study is possible only 4 weeks after the last symptom.
13. Clinically significant abnormalities on the ECG, the level of systolic blood pressure (SBP) measured in the sitting position at the time of screening <100 mm Hg or ≥ 130 mm Hg and / or diastolic blood pressure (DBP) <60 mm Hg or ≥ 85 mm Hg;
14. Heart rate less than 60 beats/min or more than 90 beats/min at the time of screening, respiratory rate less than 12 or more than 18 per minute at the time of screening, body temperature below 36.0 ° C or above 37.0 ° C at the time of screening;

15. use of any prescription and ATC drugs:

    • including herbs and food additives, vitamins that can have a significant effect on the PK of rivaroxaban or data on the effect of which on the pharmacokinetics of rivaroxaban are unknown, as well as question the characterization of the volunteer as healthy, less than 14 days before taking the drug in the first period;
    • including the use of drugs that are inducers or inhibitors of isoenzymes CYP3A4, CYP2J2 (HIV protease inhibitors, antifungal drugs of the azole group, clarithromycin, erythromycin, phenytoin, carbamazepine, phenobarbital, St. John's wort preparations, etc.), less than 30 days before taking the drug in the first period;
16. donation of plasma or blood (450 ml or more) less than 2 months (60 days) before taking the drug in the first period;
17. consumption of caffeine and xanthine-containing drinks and products (tea, coffee, chocolate, cola, etc.), products containing poppy seeds, less than 48 hours before taking the drug in the first period;
18. consumption of alcohol and alcohol-containing foods and beverages less than 48 hours before taking the drug in the first period;
19. use of citrus fruits (including grapefruit and grapefruit juice) and cranberries (including juices, fruit drinks, etc.) less than 7 days before taking the drug in the first period;
20. intake of more than 10 units alcohol per week (1 unit of alcohol is equivalent to ½ liter of beer, 200 ml dry wine or 50 ml of spirits) or history of alcoholism, drug addiction, drug abuse;
21. intense physical activity less than 24 hours before taking the drug in the first period;
22. smoking more than 10 cigarettes per day, including less than 24 hours before taking the drug in each period and during each study period;
23. participation in other clinical trials of drugs less than 3 months before taking the drug in the first period;
24. test positive for syphilis, hepatitis B, hepatitis C or HIV at the time of screening;
25. positive test for alcohol in exhaled air;
26. positive urinalysis for the content of narcotic and potent substances during screening (opiates, morphine, barbiturates, benzodiazepines, cannabinoids/marijuana);
27. the value of standard laboratory and instrumental parameters that go beyond the reference values;
28. lack of intention of volunteers to comply with the Protocol requirements throughout the course of the study and/or lack, in the opinion of the Investigator, of the volunteers' ability to understand and evaluate the information on this study as part of the informed consent form signing process, in particular regarding the expected risks and possible discomfort;
29. tattooing and piercing within 30 days prior to first drug administration;
30. difficulty swallowing tablets;
31. difficulty with taking blood (for example, difficult access to the veins).

Contacts and Locations

Contacts

Contact: Veronika Kumpel; 80173094418; specialist.fs@ft.by

Contact: Andrei Yaremchuk; 80291268246; development@ft.by

Locations

Russian Federation

Private healthcare institution "Clinical Hospital "RZD-Medicine" of the city of Yaroslavl"

Yaroslavl, Russian Federation, 150047

Contact: Alexander Khokhlov 81079109756777

Sponsors and Collaborators

Pharmtechnology LLC

ClinPharmInvest, LLC

Investigators

• Principal Investigator: Alexander Khokhlov; ClinPharmInvest, LLC

More Information

• Responsible Party: Pharmtechnology LLC
• ClinicalTrials.gov Identifier: NCT04729998
• Other Study ID Numbers: RVRX_20-2020-CPD-FRMT
• First Posted: January 29, 2021
• Last Update Posted: January 29, 2021
• Last Verified: January 2021

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Pharmtechnology LLC:

Rivaroxaban; Bioequivalence; Xarelto

Additional relevant MeSH terms:

Malnutrition; Nutrition Disorders; Rivaroxaban; Factor Xa Inhibitors; Antithrombins; Serine Proteinase Inhibitors; Protease Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action; Anticoagulants